Abs in Medical Technology

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

...randomized, double-blind phase III trial (ZODIAC). abs 31495. ASCO. 2009. (2) De Boer, R. et al. Va...a randomized, double-blind phase III trial (ZEAL). abs 31867, ASCO. 2009. (3) Natale, R. et al. Van...a randomized, double-blind phase III trial (ZEST). abs 31610. ASCO. 2009. (4) Ferlay, J. et al. GLO...

First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies

... The EXIBT Study oversight committee includes both radiation oncologists and breast surgeons. Members of the oversight committee members representing abs and ACRO with a focus on radiation oncology are: Douglas Arthur, MD, Virginia Commonwealth University, Frank Vicini, MD, William Beaumont, David Wazer...

Replidyne Provides Strategic Update

...greed to by the U.S. Food and Drug Administration (FDA), in which four Phase III clinical trials consisting of one placebo-controlled trial in each of abs and AECB and two non-inferiority trials in CAP would be adequate to submit a new drug application for faropenem covering the three indications. In Nov...

Clinical Data Presented on OrthoGlide(R) Medial Knee Implant

...with a much less invasive procedure." About Advanced Bio-Surfaces, Inc. abs is a privately held company dedicated to the development of innovative join...06 and 350 implants have been completed. For additional information contact abs at 952.912.5400 or visit the website at http://www.advbiosurf.com . ...

The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement

...on community interested in the OrthoGlide implant, abs is also involved in a clinical study. This week, d...November 10th. About Advanced Bio-Surfaces, Inc. abs is a privately held company dedicated to the devel... February 2006. For additional information contact abs at 952.912.5400 or visit the website at http://ww...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

... molecule Smac mimetic compound PhD, (SM-164) and agonist TRAIL-R Ascenta monoclonal abs (mapatumumab & Therapeutics lexatumumab). Human Genome ...